Across TCGA pan-cancer cohorts, AKAP17A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AKAP17A data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AKAP17A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AKAP17A expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where AKAP17A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.893	0.319	.007	15	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
UCEC	DFS	Quartile	III,IV	1.000	0.379	.040	4	view →
CCRCC	DFS	Tertile	III,IV	0.981	0.222	.049	2	view →
LSCC	OS	Tertile	All	0.918	0.763	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: AKAP17A tumor-vs-normal RNA expression · all AKAP17A data types